Kura Oncology, Inc. (NASDAQ:KURA) Receives $28.36 Average Target Price from Analysts

Kura Oncology, Inc. (NASDAQ:KURAGet Free Report) has earned an average rating of “Moderate Buy” from the seven research firms that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $28.36.

A number of research firms have recently weighed in on KURA. Wedbush reiterated an “outperform” rating and issued a $37.00 price objective on shares of Kura Oncology in a research note on Friday, May 3rd. JMP Securities reiterated a “market outperform” rating and issued a $32.00 price objective on shares of Kura Oncology in a research note on Tuesday. HC Wainwright reiterated a “buy” rating and issued a $32.00 price objective on shares of Kura Oncology in a research note on Tuesday, May 14th. Finally, StockNews.com lowered shares of Kura Oncology from a “hold” rating to a “sell” rating in a research note on Monday, April 15th.

Read Our Latest Research Report on Kura Oncology

Kura Oncology Trading Down 4.4 %

NASDAQ:KURA opened at $19.77 on Thursday. Kura Oncology has a 52 week low of $7.41 and a 52 week high of $24.17. The firm has a 50 day moving average of $20.54 and a 200 day moving average of $18.85. The company has a quick ratio of 16.67, a current ratio of 16.67 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $1.51 billion, a price-to-earnings ratio of -9.11 and a beta of 0.94.

Kura Oncology (NASDAQ:KURAGet Free Report) last posted its earnings results on Thursday, May 2nd. The company reported ($0.59) EPS for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.03). The business’s revenue was up .0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.50) EPS. As a group, sell-side analysts anticipate that Kura Oncology will post -2.56 earnings per share for the current fiscal year.

Insider Activity at Kura Oncology

In other Kura Oncology news, insider Teresa Brophy Bair sold 2,615 shares of the stock in a transaction on Monday, May 20th. The shares were sold at an average price of $22.15, for a total transaction of $57,922.25. Following the transaction, the insider now directly owns 68,979 shares of the company’s stock, valued at $1,527,884.85. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 5.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On Kura Oncology

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Signaturefd LLC lifted its holdings in Kura Oncology by 40.4% during the fourth quarter. Signaturefd LLC now owns 5,038 shares of the company’s stock valued at $72,000 after purchasing an additional 1,449 shares in the last quarter. Pale Fire Capital SE purchased a new position in Kura Oncology during the third quarter valued at $92,000. E Fund Management Co. Ltd. lifted its stake in shares of Kura Oncology by 12.2% in the third quarter. E Fund Management Co. Ltd. now owns 11,929 shares of the company’s stock worth $109,000 after buying an additional 1,301 shares in the last quarter. SG Americas Securities LLC purchased a new position in shares of Kura Oncology in the first quarter worth about $110,000. Finally, AXQ Capital LP purchased a new position in shares of Kura Oncology in the third quarter worth about $118,000.

About Kura Oncology

(Get Free Report

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.

Featured Articles

Analyst Recommendations for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.